SecBot SecBot
PRESS-RELEASE ·Filed May 5, 2026

QURE

uniQure Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The earnings miss and widening loss are near-term negatives, but the stock's direction will hinge on upcoming regulatory catalysts for AMT-130 (FDA Type B meeting in Q2, MHRA MAA submission in Q3). Traders should watch for any FDA feedback that could derail or accelerate the path to approval, as well as the four-year AMT-130 data analysis expected in Q3 2026.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$21.16
T+0 close · May 5, 2026 · via day close
Latest settled
+99.39%
T+60 · $42.19
Vs SPY
+96.65%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $21.16entry
  2. T+1 · 7mo ago +7.84%α +6.46% · $22.82
  3. T+5 · 6mo ago +30.62%α +28.64% · $27.64
  4. T+20 · 6mo ago +26.46%α +21.51% · $26.76
  5. T+60 · 4mo ago +99.39%α +96.65% · $42.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

uniQure reported Q1 2026 EPS of -$0.85, missing the consensus estimate of -$0.75 by 13.3%, and revenue of $3.6M, below the $4.5M consensus. The net loss widened to $53.5M from $43.6M a year ago, driven by a $9.2M increase in SG&A expenses. The stock may react negatively to the earnings miss and widening loss, though the company's strong cash position ($586.6M) and upcoming regulatory milestones for AMT-130 provide some offset.

Key Financial Metrics

EPS
−$0.85
est −$0.75 · -13.3%
Revenue
$3.6M
est $4.5M · -20.8% · +127.3% YoY
Rating
miss

Key Facts

  • Q1 2026 EPS of -$0.85 missed consensus of -$0.75 by 13.3%
  • Q1 2026 revenue of $3.6M missed consensus of $4.5M by 20%
  • Net loss widened to $53.5M from $43.6M in Q1 2025
  • SG&A expenses surged 84% to $20.1M from $10.9M a year ago
  • Cash, cash equivalents and investment securities of $586.6M as of March 31, 2026
  • Cash runway into second half of 2029
  • FDA Type B meeting for AMT-130 scheduled for Q2 2026
  • MAA submission for AMT-130 to UK MHRA expected in Q3 2026
  • AMT-260 Phase I/IIa data from first cohort expected at Epilepsy Foundation Pipeline Conference June 18-19, 2026
  • AMT-162 development discontinued after dose-limiting toxicity

Financial Impact

EPS miss of 13.3% and revenue miss of 20% vs consensus; net loss widened by $9.9M YoY

epsrevenuenet losssg&a expenses

Risk Factors

  • FDA may not agree that Phase I/II data plus external control are sufficient for BLA, requiring a new costly trial
  • SG&A expense growth may continue as the company builds commercial infrastructure for AMT-130
  • AMT-260 and AMT-191 clinical data may disappoint
  • Liability from royalty financing agreement of $482.3M could pressure future cash flows

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287519

Track record

38 reports on QURE

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
  2. Nov 4, 202612d ago 8-K Bullish 7/10 No price data
  3. Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  5. Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  6. Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
  8. Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
  9. Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (11h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026